Portage Biotech Inc. (PRTG)

Portage Biotech Income Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Selling, General & Admin	6.16	8.36	8.82	5.13	1.87	0.86
Research & Development	12.87	8.21	6.77	7.31	4.11	1.91
Other Operating Expenses	44.57	43.86	0	0	0	0
Operating Expenses	63.59	60.44	15.59	12.44	5.98	2.76
Operating Income	-63.59	-60.44	-15.59	-12.44	-5.98	-2.76
Interest Expense / Income	0.02	0.01	0.04	0.18	0.56	0.09
Other Expense / Income	106.8	62.08	-0.81	2.28	-0.03	0.74
Pretax Income	-170.41	-122.52	-14.82	-14.89	-6.51	-3.59
Income Tax	-25.5	-17.86	4.35	2.3	0.74	0
Net Income	-144.91	-104.67	-19.17	-17.19	-7.25	-3.59
Shares Outstanding (Basic)	21	16	13	12	11	5
Shares Outstanding (Diluted)	21	16	13	12	11	5
Shares Change	22.64%	23.42%	11.31%	7.13%	127.22%	78.76%
EPS (Basic)	-8.34	-6.49	-1.29	-1.35	-0.49	-0.55
EPS (Diluted)	-8.34	-6.49	-1.29	-1.35	-0.49	-0.55
Free Cash Flow	-15.86	-12.08	-6.76	-4.28	-3.71	-0.86
Free Cash Flow Per Share	-0.76	-0.75	-0.52	-0.36	-0.34	-0.18
EBITDA	-170.35	-122.51	-14.77	-14.72	-5.95	-3.51
Depreciation & Amortization	0.04	0	0	0	0	0
EBIT	-170.39	-122.51	-14.77	-14.72	-5.95	-3.51

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).